| Market Capitalization (Millions $) |
88 |
| Shares
Outstanding (Millions) |
69 |
| Employees |
112 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-85 |
| Cash Flow (TTM) (Millions $) |
-14 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Inovio Pharmaceuticals Inc is a biotechnology company that focuses on the development and commercialization of DNA immunotherapies to treat and prevent infectious diseases, cancer, and other medical conditions. The company's innovative platform, called SynCon, allows for the rapid design and production of DNA-based vaccines and immune therapies. Inovio's technology aims to stimulate the body's immune system to target specific diseases, potentially providing safer and more effective treatment options.
Inovio has a diverse pipeline of product candidates in various stages of development, including treatments for HPV-related cancers, hepatitis B, HIV, and Zika virus, among others. The company has also recently gained attention for its efforts in developing a COVID-19 vaccine candidate, which has shown promising results in preclinical studies.
In addition to its research and development activities, Inovio has collaborations and partnerships with various organizations, including academic institutions, biopharmaceutical companies, and government agencies, to further advance its technology and expand its product portfolio.
Overall, Inovio Pharmaceuticals Inc is committed to leveraging its innovative DNA-based platform to address unmet medical needs and improve patient outcomes in the field of immunotherapy.
Company Address: 660 W. Germantown Pike Plymouth Meeting 19462 PA
Company Phone Number: 440-4200 Stock Exchange / Ticker: NASDAQ INO
|
1.75%